NCT03528915

Brief Summary

The French guidelines for the use of Rifamycine eye drops in delivery room to prevent neonatal conjunctivitis have been actualized. Only newborns exposed to risk factors of conjunctivitis should be treated, compared to previous guidelines, treating all newborns. currently, there are no data describing risk factors for neonatal conjunctivitis. This study evaluated the incidence of conjunctivitis with or without Rifamycine eye drops treatment in the delivery room. Then risk factors for neonatal conjunctivitis where analyzed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
881

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2015

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 9, 2015

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 12, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 24, 2016

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

April 19, 2018

Completed
29 days until next milestone

First Posted

Study publicly available on registry

May 18, 2018

Completed
Last Updated

January 23, 2019

Status Verified

January 1, 2019

Enrollment Period

8 months

First QC Date

April 19, 2018

Last Update Submit

January 21, 2019

Conditions

Keywords

neonate, infant; eyewash; delivery room; prophylaxis; risk factor's

Outcome Measures

Primary Outcomes (1)

  • Occurrence of conjunctivitis during the first 8 days of life in newborns

    8 days

Study Arms (2)

Prophylaxis group

Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.

Other: Rifamycine treatment

no-antibiotic group

Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.

Other: whithout Rifamycine treatment

Interventions

Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.

Prophylaxis group

Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.

no-antibiotic group

Eligibility Criteria

Age36 Weeks - 36 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Newborns

You may qualify if:

  • Newborns at the University Hospital of Amiens\> 36SA,
  • Admitted in maternity at the exit of nursery

You may not qualify if:

  • Newborns at the Amiens University Hospital \<36SA
  • Eye drops for any medical reason within the first day of life.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Amiens-Picardie

Amiens, 80054, France

Location

MeSH Terms

Conditions

Ophthalmia Neonatorum

Condition Hierarchy (Ancestors)

Conjunctivitis, BacterialEye Infections, BacterialBacterial InfectionsBacterial Infections and MycosesInfectionsNeisseriaceae InfectionsGram-Negative Bacterial InfectionsEye InfectionsConjunctivitisConjunctival DiseasesEye DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 19, 2018

First Posted

May 18, 2018

Study Start

September 9, 2015

Primary Completion

May 12, 2016

Study Completion

July 24, 2016

Last Updated

January 23, 2019

Record last verified: 2019-01

Locations